Chongqing Genrix Biopharmaceutical Co Ltd

688443

Company Profile

  • Business description

    Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

  • Contact

    No. 699, Maliu Avenue
    Area A, Building 2
    International Bio City
    Banan
    Chongqing401338
    CHN

    T: +86 2361758666

    http://www.genrixbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    743

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,841.908.300.09%
CAC 407,694.0760.48-0.78%
DAX 4023,796.92137.21-0.57%
Dow JONES (US)44,828.53344.110.77%
FTSE 1008,825.532.330.03%
HKSE23,916.06153.88-0.64%
NASDAQ20,601.10207.971.02%
Nikkei 22539,810.8824.980.06%
NZX 50 Index12,766.6062.120.49%
S&P 5006,279.3551.930.83%
S&P/ASX 2008,603.007.200.08%
SSE Composite Index3,472.3211.170.32%

Market Movers